查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1931198

避孕藥物輸送裝置市場依產品類型、技術、最終用戶和通路分類，全球預測（2026-2032年）

Contraceptive Drug Eluting Devices Market by Product Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年避孕藥物釋放裝置市場規模為6.4264億美元，預計到2026年將成長至7.0089億美元，到2032年將達到12.793億美元，複合年成長率為10.33%。

關鍵市場統計數據
基準年 2025 6.4264億美元
預計年份：2026年 7.089億美元
預測年份 2032 12.793億美元
複合年成長率 (%) 10.33%

緩釋避孕裝置融合了醫療設備工程和生殖醫學，將緩釋藥物技術與植入式或陰道內給藥平台結合，以最佳化避孕效果、便利性和依從性。過去十年，聚合物科學、裝置傳輸機制和以患者為中心的護理模式的不斷進步，徹底改變了臨床醫生和患者對長效可逆避孕方法的評估方式，使這些技術成為各種臨床環境中的核心選擇。

隨著避孕選擇從臨時性生育計畫轉向終身生育計劃，相關人員在尋求符合生活方式、生育次數和年齡相關偏好的產品特性時，更加重視產品的可靠性、可逆性和安全性。同時，監管路徑和臨床試驗設計也在不斷發展，更加重視實際應用效果和長期安全性數據，從而重塑了產品開發週期。鑑於藥物釋放性能的穩定性需要特殊的聚合物和無菌工藝，供應鏈的韌性和生產品質在採購決策中扮演越來越重要的角色。

綜上所述，這些趨勢凸顯了將臨床價值提案與監管應對力和生產規模化相結合的策略重要性。本導論部分概述了技術、臨床和商業性方面的內容，為後續章節奠定了基礎，並闡述了製造商、醫療服務提供者和支付方應如何解讀醫療器材的差異化和應用路徑。

透過改變臨床實務、聚合物創新、數位整合和個人化醫療，實現避孕藥物釋放裝置的變革性轉型。

生物可分解和不可分解聚合物平台目前支援更廣泛的釋放曲線和持續時間，使多種產品原型能夠更好地滿足患者偏好和臨床應用需求。同時，植入和取出技術的改進，以及針對醫護人員的培訓模式，正在降低先前限制其廣泛應用的程序障礙。

美國在2025年推出或擴大關稅措施對供應鏈、製造選擇、臨床應用以及跨境醫療設備分銷的累積影響

美國在2025年推出或擴大的關稅措施對避孕藥物緩釋裝置的價值鏈產生了一系列複雜的影響，其累積效應遠不止於進口關稅本身。影響原料聚合物、專用組件和成品裝置的關稅可能會增加到岸成本，並促使採購商和製造商重新評估籌資策略和整體擁有成本。為此，企業可能會加快供應商網路的多元化，尋求在美洲的近岸外包機會，或透過重新談判長期供應商合約來尋求投入價格的穩定。

關鍵細分洞察揭示了影響產品類型、聚合物技術、終端用戶環境、分銷管道和人口統計群體等因素，從而推動了產品採用趨勢的發展。

市場區隔揭示了需求、臨床適用性和營運優先事項在產品、技術、終端用戶、分銷和人口統計等維度上的交匯點。依產品類型細分，可區分植入、子宮內避孕系統和避孕環，每種產品都有其獨特的持續時間和使用特性。植入的評估週期從短到長不等，例如3年和5年的設計。子宮內避孕系統涵蓋了常見的3年、5年和7年使用週期選擇。而避孕環則設計為每月或每季更換一次。這些產品差異會影響臨床諮詢、追蹤頻率和器材生命週期等方面的考量。

重點區域洞察，著重分析需求促進因素、政策趨勢、供應鏈韌性以及主要區域的病患就醫差異

區域趨勢導致需求模式、監管壓力和供應鏈限制存在差異，製造商必須應對這些差異。在美洲，完善的臨床基礎設施以及對生殖健康的政策重點推動了相關技術在診所和醫院管道的廣泛應用；同時，供應鏈韌性舉措和生產獎勵正在影響特種聚合物和無菌組裝的採購決策。

企業策略和競爭動態影響產品創新、製造地、監管路徑和夥伴關係模式。

避孕藥物輸送裝置領域的主要企業正朝著一系列策略重點邁進，這些重點將塑造其競爭動態。產品差異化取決於聚合物的選擇和釋放動力學、植入和取出操作的便利性以及整合的患者支援服務，包括數位追蹤和依從性工具。那些早期投資於可擴展的無菌生產、完善的品質系統和多元化採購的企業，將在產品上市速度和穩定的利潤率方面獲得優勢。

為產業領導者提供切實可行的建議，以加速創新、加強供應鏈、協調監管策略並擴大患者獲取途徑。

我們鼓勵產業領導者採取務實的分階段方法，兼顧短期營運韌性和長期創新。首先，應優先考慮供應鏈韌性，並透過識別關鍵聚合物和組件供應商、選擇備用供應商以及評估區域製造地的可行性來降低關稅和物流風險。投資於檢驗的契約製造關係和冗餘滅菌能力，既能降低中斷風險，又能維持資本效率。

調查方法包括資料收集、初步訪談、臨床和監管資訊、供應鏈圖譜繪製以及定性情境建構。

本研究結合了結構化一手訪談、有針對性的二手資料以及臨床、監管和供應鏈資料的整合，建構了強力的證據基礎。一手研究包括對臨床醫生、採購專業人員、聚合物供應商、契約製造和監管顧問進行結構化訪談，以收集關於醫療設備可用性、採購障礙和生產限制的第一手觀點。二級資訊來源包括同行評審的臨床文獻、監管指導文件、專利趨勢訊號和臨床檢驗註冊資訊，以對產品性能和核准途徑進行三角驗證。

全面概述了避孕藥物輸送裝置未來發展的臨床、技術和商業性影響。

總之，避孕藥物緩釋裝置兼具臨床價值、材料創新和商業性機遇，但要充分發揮其潛力，需要在產品開發、監管策略和供應鏈管理等方面通力合作。可生物分解和不可生物分解聚合物的進步拓展了藥物緩釋持續時間和使用者體驗的選擇範圍，而不斷發展的護理模式和數位化支持則豐富了諮詢和追蹤途徑。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的避孕藥物輸送裝置市場

  • 植入
  • 子宮內系統
  • 陰道環

9. 依技術分類的避孕藥物輸送裝置市場

  • 可生物分解聚合物
    • PLA
    • PLGA
  • 不可生物分解聚合物
    • 乙烯-醋酸乙烯酯
    • 矽酮

10. 依最終用戶分類的避孕藥物輸送裝置市場

  • 診所
    • 計劃生育中心
    • 婦產科診所
  • 居家照護
  • 醫院
  • 專業中心

11. 依分銷管道分類的避孕藥物輸送裝置市場

  • 離線
  • 線上

12. 依地區分類的避孕藥物輸送裝置市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 依組別分類的避孕藥物輸送裝置市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國避孕藥物輸送裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國避孕藥物傳輸裝置市場

16. 中國：避孕藥物輸送裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actavis plc
  • Agile Therapeutics, Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Evofem Biosciences, Inc.
  • GlaxoSmithKline plc
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Warner Chilcott plc
Product Code: MRR-7B550E008DB2

The Contraceptive Drug Eluting Devices Market was valued at USD 642.64 million in 2025 and is projected to grow to USD 700.89 million in 2026, with a CAGR of 10.33%, reaching USD 1,279.30 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 642.64 million
Estimated Year [2026] USD 700.89 million
Forecast Year [2032] USD 1,279.30 million
CAGR (%) 10.33%

Contraceptive drug-eluting devices are at the intersection of medical device engineering and reproductive health therapeutics, combining sustained-release pharmacology with implantable or intravaginal platforms to optimize efficacy, convenience and adherence. Over the past decade, incremental improvements in polymer science, device delivery mechanisms and patient-centric care models have transformed how clinicians and patients evaluate long-acting reversible contraception, making these technologies core options across diverse care settings.

As attention moves from episodic contraception to lifecycle reproductive planning, stakeholders are prioritizing reliability, reversibility and safety while also demanding product attributes that align with lifestyle, parity and age-related preferences. Concurrently, regulatory pathways and clinical trial design have evolved to emphasize real-world performance and long-term safety data, reshaping product development timelines. Supply chain resilience and manufacturing quality are increasingly visible factors in procurement decisions, given the specialized polymers and sterile processes required for consistent drug-eluting performance.

Taken together, these forces highlight the strategic importance of aligning clinical value propositions with regulatory readiness and manufacturing scalability. The introduction frames the technical, clinical and commercial dimensions that inform subsequent sections, establishing a foundation for how manufacturers, providers and payers should interpret device differentiation and adoption pathways.

Transformative shifts redefining contraceptive drug-eluting devices through clinical practice changes, polymer innovations, digital integration and personalized care

Several transformative shifts are reshaping the landscape for contraceptive drug-eluting devices, driven by advances in polymer chemistry, digital health integration and evolving clinical expectations. Biodegradable and non-biodegradable polymer platforms now support a wider range of release profiles and durations, enabling multiple product archetypes that better match patient preferences and clinical use cases. At the same time, improvements in insertion and removal techniques, coupled with provider training models, are lowering procedural barriers that historically limited uptake.

Simultaneously, the rise of telehealth and remote care pathways is altering how patients access counseling, follow-up and adverse event management, creating opportunities for hybrid models that blend clinic-based procedures with home-based support. Regulators are adapting to this reality by placing greater emphasis on post-market surveillance and real-world evidence, prompting manufacturers to design data-collection features and registry partnerships into launch plans. Supply chain diversification and nearshoring initiatives are also accelerating, prompted by geopolitical uncertainty and the need to secure specialized polymers and sterile manufacturing capacity.

Consequently, competitive differentiation increasingly rests on integrated value propositions that combine clinical performance, patient experience and operational resilience. As a result, product roadmaps, partnership strategies and go-to-market plans are being recalibrated to capture both short-term clinical demand and longer-term population health objectives.

Cumulative effects of United States tariff measures in 2025 on supply chains, manufacturing choices, clinical access and cross-border device distribution

United States tariff measures introduced or expanded in 2025 present a complex set of implications for the contraceptive drug-eluting device value chain, with cumulative effects that extend beyond headline import duties. Tariffs that affect raw polymer feedstocks, specialty components and finished devices can increase landed costs, prompting buyers and manufacturers to reassess sourcing strategies and total cost of ownership. In response, firms may accelerate diversification of supplier networks, pursue nearshoring opportunities in the Americas, or renegotiate long-term supplier contracts to stabilize input prices.

These trade policy shifts also influence manufacturing location decisions. Companies dependent on high-volume, low-cost production in Asia may evaluate the trade-offs of relocating assembly or critical steps closer to end markets to mitigate tariff exposure and reduce lead-time variability. At the same time, transitional supply chain moves require investment in validation, regulatory filings and sterile manufacturing capacity, which can extend product timelines unless planned proactively.

Clinicians and healthcare purchasers may face short-term price pressure that affects formulary placement, procurement cycles and procurement negotiations. Moreover, tariff-driven supply constraints can amplify the value of contract manufacturing relationships and strategic inventories, particularly for devices using specialized biodegradable polymers such as PLA and PLGA or non-biodegradable materials like ethylene vinyl acetate and silicone. Ultimately, prudent scenario planning and proactive supply chain resilience measures will be essential to manage the operational and commercial consequences of tariff changes while maintaining patient access and manufacturer viability.

Key segmentation insights revealing product types, polymer technologies, end-user settings, distribution channels and demographic cohorts shaping adoption

Segmentation reveals where demand, clinical fit and operational priorities converge across product, technology, end user, distribution and demographic dimensions. Product type segmentation distinguishes implants, intrauterine systems and vaginal rings, each with distinct duration and dosing characteristics: implants are evaluated across shorter and longer durations such as three-year and five-year designs, intrauterine systems span options commonly studied across three-, five- and seven-year durations, while vaginal rings are designed either for monthly or quarterly change intervals. These product distinctions drive clinical counseling, follow-up cadence and device lifecycle considerations.

Technology segmentation differentiates biodegradable polymer platforms from non-biodegradable substrates. Within biodegradable polymers, polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) are central to sustained-release strategies, offering controlled resorption profiles. Non-biodegradable polymers such as ethylene vinyl acetate and silicone deliver stable matrices for extended hormone delivery, with distinct implications for removal procedures and long-term device behavior.

End-user segmentation highlights the settings where devices are delivered and supported: clinics-including family planning centers and OB-GYN clinics-remain primary access points, complemented by hospitals, specialty centers and expanding models for home care follow-up. Distribution channels span hospital pharmacies, online pharmacies and retail pharmacy networks, each with unique logistical and regulatory checkpoints. Demographic segmentation emphasizes the importance of age cohorts, frequently grouped as 15-24, 25-34, 35-44 and 45+, and parity distinctions between multiparous and nulliparous patients. Together, these segmentation layers inform product positioning, messaging, training requirements and post-market evidence strategies because they determine clinical relevance, usability expectations and reimbursement pathways.

Key regional insights highlighting demand drivers, policy dynamics, supply chain resilience and patient access differences across major global regions

Regional dynamics create differentiated demand patterns, regulatory pressures and supply chain constraints that manufacturers must navigate. In the Americas, a combination of established clinical infrastructure and policy focus on reproductive health supports broad adoption across clinic and hospital channels, while supply chain resilience initiatives and manufacturing incentives are influencing sourcing decisions for specialized polymers and sterile assembly.

Europe, Middle East & Africa presents a more heterogeneous landscape where regulatory frameworks vary substantially and affordability considerations shape procurement pathways; in some markets centralized public procurement and reimbursement mechanisms accelerate scale-up, whereas in others fragmented payer systems and distribution challenges demand tailored market entry strategies. Meanwhile, policy debates around reproductive health access and import regulation can materially affect timing and uptake.

Asia-Pacific is marked by rapid product innovation adoption in urban centers, expanding private clinic networks and strong manufacturing ecosystems for polymers and device components. However, regional variations in regulatory harmonization and reimbursement mean that commercial approaches must balance centralized launches with country-specific clinical evidence and engagement plans. Across all regions, governments and health systems are increasingly prioritizing equitable access and long-term safety monitoring, which in turn raises the strategic value of real-world evidence programs and durable local partnerships.

Company strategies and competitive dynamics shaping product innovation, manufacturing footprints, regulatory pathways and partnership models in the device sector

Leading companies in the contraceptive drug-eluting device space are converging on a set of strategic priorities that shape competitive dynamics. Product differentiation is being driven by polymer selection and release kinetics, procedural ease of insertion and removal, and integrated patient support services that include digital follow-up and adherence tools. Firms that invest early in scalable sterile manufacturing, robust quality systems and diversified component sourcing gain advantages in speed-to-market and margin resilience.

Partnering strategies are also prominent: licensors, contract manufacturers and clinical research organizations are often engaged to compress development timelines, share regulatory risk and extend geographic reach. Companies with established relationships across clinical networks and family planning programs tend to secure earlier adoption, particularly when combined with provider training and reimbursement support. Regulatory strategy is an increasingly strategic discipline, with leading firms designing pre-submission engagements and phased post-market evidence plans to align with varying global regulatory expectations.

Finally, innovation priorities include not only material science and device form factors but also patient experience improvements and lifecycle services that lower total cost of care. Firms that align R&D, commercial and policy engagement to deliver measurable clinical advantages and operational dependability will be best positioned to capture sustainable value.

Actionable recommendations for industry leaders to accelerate innovation, strengthen supply chains, align regulatory strategy and expand patient access

Industry leaders should adopt a pragmatic, phased approach that balances near-term operational resilience with long-term innovation. First, prioritize supply chain resilience by identifying critical polymer and component suppliers, qualifying secondary sources, and assessing the feasibility of regional manufacturing hubs to mitigate tariff and logistics risks. Investing in validated contract manufacturing relationships and redundant sterilization capacity can reduce disruption risk while preserving capital efficiency.

Second, integrate regulatory and clinical evidence planning from project inception. Early engagement with regulators and the design of real-world evidence strategies will shorten approval timelines and facilitate broader payer conversations. Manufacturers should build registries and post-market data collection into launch budgets to demonstrate safety, user satisfaction and comparative outcomes across age and parity cohorts.

Third, tailor commercial models to segmentation insights: align product duration and ring cadence with demographic and parousity preferences, and customize training resources for family planning centers and OB-GYN clinics. Leverage digital health tools to extend counseling and follow-up, thereby lowering clinic burden and improving adherence. Finally, pursue flexible pricing and distribution arrangements with hospital pharmacies, online pharmacies and retail channels to enhance access while protecting margins. Taken together, these actions create a resilient foundation for scaling responsibly and competitively.

Research methodology explaining data collection, primary interviews, clinical and regulatory intelligence, supply chain mapping and qualitative scenario development

The research combines structured primary interviews, targeted secondary intelligence and synthesis of clinical, regulatory and supply chain data to create a robust evidence base. Primary research included structured interviews with clinicians, procurement specialists, polymer suppliers, contract manufacturers and regulatory advisors to capture frontline perspectives on device usability, procurement barriers and manufacturing constraints. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, patent landscape signals and clinical trial registries to triangulate product performance and approval pathways.

Analytical methods incorporated thematic coding of qualitative interviews, crosswalks between product attributes and end-user needs, and supply chain mapping to identify single points of failure and sourcing concentration risk. Scenario analysis was used to evaluate tariff and policy shifts, testing implications for manufacturing location decisions and distribution channel economics. Quality control measures included cross-validation of critical inputs, expert panel review of key assumptions and iterative feedback loops with clinical advisors to ensure that conclusions reflect practical clinical realities rather than theoretical constructs.

This mixed-methods approach delivers actionable insights by connecting material science and device engineering to clinical workflows, reimbursement realities and operational logistics, thereby supporting evidence-based strategic choices.

Concluding perspectives synthesizing clinical, technological and commercial implications for the future trajectory of contraceptive drug-eluting devices

In conclusion, contraceptive drug-eluting devices present a compelling convergence of clinical value, material innovation and commercial opportunity, yet realizing that potential requires coordinated action across product development, regulatory strategy and supply chain management. Advances in biodegradable and non-biodegradable polymers expand the toolbox for tailoring duration and user experience, while evolving care models and digital support expand channels for counseling and follow-up.

Strategic imperatives include securing diversified supply chains, embedding real-world evidence into launch plans, and aligning product features with demographic and end-user segmentation to maximize clinical relevance. Geopolitical developments and tariff measures add urgency to resilience planning but also create incentives for regional manufacturing and partnership models that can improve responsiveness and reduce lead times. Ultimately, organizations that marry technological differentiation with operational discipline and patient-centered commercialization will set the standard for sustainable adoption and meaningful public health impact.

The path forward will be iterative, requiring continuous monitoring of regulatory shifts, clinical outcomes and supply dynamics, but the combination of targeted investment and disciplined execution can unlock durable value across clinical, commercial and policy dimensions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Drug Eluting Devices Market, by Product Type

  • 8.1. Implant
  • 8.2. Intrauterine System
  • 8.3. Vaginal Ring

9. Contraceptive Drug Eluting Devices Market, by Technology

  • 9.1. Biodegradable Polymer
    • 9.1.1. PLA
    • 9.1.2. PLGA
  • 9.2. Non-Biodegradable Polymer
    • 9.2.1. Ethylene Vinyl Acetate
    • 9.2.2. Silicone

10. Contraceptive Drug Eluting Devices Market, by End User

  • 10.1. Clinics
    • 10.1.1. Family Planning Centers
    • 10.1.2. OB-GYN Clinics
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Specialty Centers

11. Contraceptive Drug Eluting Devices Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Contraceptive Drug Eluting Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Contraceptive Drug Eluting Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Contraceptive Drug Eluting Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Contraceptive Drug Eluting Devices Market

16. China Contraceptive Drug Eluting Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Actavis plc
  • 17.6. Agile Therapeutics, Inc.
  • 17.7. Allergan plc
  • 17.8. Amgen Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Bayer AG
  • 17.11. Bristol-Myers Squibb Company
  • 17.12. Eli Lilly and Company
  • 17.13. Evofem Biosciences, Inc.
  • 17.14. GlaxoSmithKline plc
  • 17.15. HRA Pharma
  • 17.16. Johnson & Johnson
  • 17.17. Merck & Co., Inc.
  • 17.18. Mylan N.V.
  • 17.19. Novartis AG
  • 17.20. Novo Nordisk A/S
  • 17.21. Pfizer Inc.
  • 17.22. Roche Holding AG
  • 17.23. Sanofi S.A.
  • 17.24. Sun Pharmaceutical Industries Ltd.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Warner Chilcott plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY VAGINAL RING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY VAGINAL RING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY VAGINAL RING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLGA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLGA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLGA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OB-GYN CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OB-GYN CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OB-GYN CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)